284 results on '"S. Scuderi"'
Search Results
2. Initial steps of an online search tool development for diagnostic and prognostic factors in prostate cancer
3. Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
4. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
5. The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
6. Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
7. Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
8. Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
9. Can we improve our ability to assess primary tumor stage of prostate cancer in patients with MRI-visible lesions? development and external validation of a novel T-stage classification based on clinical and MRI findings
10. Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
11. Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy
12. Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
13. The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
14. A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
15. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
16. Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series
17. Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
18. The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
19. A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
20. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection
21. The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with oligometastatic prostate cancer: an external validation study
22. Impact of histological variants in node positive patients treated with radical cystectomy for bladder cancer
23. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database
24. No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study
25. Limited vs extended lymph node dissection in T1G3 bladder cancer patients treated with radical cystectomy: is this group responsible for the negative results of the LEA trial?
26. Incongruence between turb and radical cystectomy findings in terms of histological variant identification: analysis of all potential clinical risk factors
27. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
28. How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
29. No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study
30. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
31. The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
32. Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: Analysis of all potential clinical risk factors
33. Outcome of non-responders to neoadjuvant immunotherapy compared to cisplatin-based chemotherapy before radical cystectomy in muscle-invasive bladder cancer
34. Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
35. When to omit lymphadenectomy during radical prostatectomy in patients with clinical localized prostate cancer: A clinical net benefit analysis weighting staging accuracy, risk of morbidity and life expectancy
36. Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
37. Can we improve our ability to assess primary tumor stage of prostate cancer in patients with MRI-visible lesions? Development and external validation of a novel T-stage classification based on clinical and MRI findings
38. Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
39. A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
40. The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
41. SARG: the high resolution spectrograph
42. The ASTRI Mini-Array of Cherenkov Telescopes at the Observatorio del Teide
43. Exploring the effect of metastasis directed therapy on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer
44. Impact of pre-operative PSMA PET/CT for men with cN0M0 conventional imaging and pN+ prostate cancer: Results from a multicenter study
45. A systematic review to evaluate Patient-Reported Outcomes Measures (PROMs) for metastatic prostate cancer according to the COSMIN methodology – A PIONEER wp2 project
46. Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?
47. Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy
48. Impact of radiologist expertise on PI-RADS distribution and detection of clinically significant prostate cancer: Results from a single, high volume center
49. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification
50. Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric MRI? A topographic mapping study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.